Markers of cancer prognosis and immunotherapy suitability and uses thereof

By detecting the expression of CXCL10, MMP9, VSIG4, ARL4C, CXCL13, and PRRX1 genes in colorectal cancer patients, and using a risk scoring formula to assess cancer prognosis and the suitability for immunotherapy, this approach addresses the lack of accurate biomarkers in existing technologies and enables precise, individualized treatment guidance.

CN116121390BActive Publication Date: 2026-07-24AMOY DIAGNOSTICS CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
AMOY DIAGNOSTICS CO LTD
Filing Date
2023-02-13
Publication Date
2026-07-24

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The application provides a marker for cancer prognosis and immunotherapy applicability and application thereof. The application also provides a risk prediction model based on the marker, and further obtains a risk score, so that the prognosis of cancer and the applicability of immunotherapy can be predicted by the risk score. The application provides a reliable way for the prognosis of cancer patients and immunotherapy. The application also discloses a detection system for predicting the prognosis of cancer and the applicability of immunotherapy, and a method for predicting the prognosis of cancer and the applicability of immunotherapy.
Need to check novelty before this filing date? Find Prior Art